Literature DB >> 6767793

Estimating the extra charges and prolongation of hospitalization due to nosocomial infections: a comparison of methods.

R W Haley, D R Schaberg, S D Von Allmen, J E McGowan.   

Abstract

Estimates of the economic consequences of nosocomial infections were derived by studying the same patient population with two different methods: physician's assessment and comparisons of patients with nosocomial infection and those without, matched on five characteristics. Estimates of extra days and extra routine charges obtained by the comparison were about 2 1/2 times greater than those obtained by the physician's assessment (P less than 0.0001). Even when the match of patients was exact and measures were taken to avoid confounding, patients with nosocomial infection had more discharge diagnoses recorded (P = 0.02) and experienced more episodes of pulmonary embolism, renal failure, and death in the hospital than did their counterparts. These differences suggest that, despite careful matching, the members of the pairs were not comparable in their intrinsic predisposition to prolonged hospitalization. Unless patients can be matched on this prediposition, the estimates from a comparison study will be exaggerated.

Entities:  

Mesh:

Year:  1980        PMID: 6767793     DOI: 10.1093/infdis/141.2.248

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Economic aspects of innovations in medical technology.

Authors:  P Oberender; S Ruckdäschel; S Lugauer; J P Guggenbichler
Journal:  Infection       Date:  1999       Impact factor: 3.553

2.  Surgical site infection - a European perspective of incidence and economic burden.

Authors:  David J Leaper; Harry van Goor; Jacqueline Reilly; Nicola Petrosillo; Heinrich K Geiss; Antonio J Torres; Anne Berger
Journal:  Int Wound J       Date:  2004-12       Impact factor: 3.315

3.  Transmission dynamics of methicillin-resistant Staphylococcus aureus in a medical intensive care unit.

Authors:  Ian M Hall; Iain Barrass; Steve Leach; Didier Pittet; Stéphane Hugonnet
Journal:  J R Soc Interface       Date:  2012-05-09       Impact factor: 4.118

Review 4.  Costs of hospital-acquired infection and transferability of the estimates: a systematic review.

Authors:  H Fukuda; J Lee; Y Imanaka
Journal:  Infection       Date:  2011-03-22       Impact factor: 3.553

5.  Towards a global perspective of nosocomial infections.

Authors:  R P Wenzel
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

6.  Using cost of infection as a tool to demonstrate a difference in prophylactic antibiotic efficacy: a prospective randomized comparison of the pharmacoeconomic effectiveness of ceftriaxone and cefotaxime prophylaxis in abdominal surgery.

Authors:  John C Woodfield; Andre M Van Rij; Ross A Pettigrew; Antje van der Linden; Donna Bolt
Journal:  World J Surg       Date:  2005-01       Impact factor: 3.352

7.  Incidence and risk factors for surgical site infection following open reduction and internal fixation of adult tibial plateau fractures.

Authors:  Jia Li; Yanbin Zhu; Bo Liu; Tianhua Dong; Wei Chen; Yingze Zhang
Journal:  Int Orthop       Date:  2017-12-21       Impact factor: 3.075

8.  Nosocomial infection in surgery wards: a controlled study of increased duration of hospital stays and direct cost of hospitalization.

Authors:  A A Vegas; V M Jodra; M L García
Journal:  Eur J Epidemiol       Date:  1993-09       Impact factor: 8.082

9.  Preoperative stay as a risk factor for nosocomial infection.

Authors:  A Bueno Cavanillas; R Rodrìguez-Contreras; M Delgado Rodriguez; O Moreno Abril; R López Gigosos; J Guillen Solvas; R Gálvez Vargas
Journal:  Eur J Epidemiol       Date:  1991-11       Impact factor: 8.082

10.  Prolongation of hospital stay and extra costs due to ventilator-associated pneumonia in an intensive care unit.

Authors:  I Kappstein; G Schulgen; U Beyer; K Geiger; M Schumacher; F D Daschner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-06       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.